Global leadership in corticosteroid and steroidal hormone APIs.
Long-standing relationships with domestic and global customer base.
Fully-invested, multi-scale, vertically integrated manufacturing platform with sustainable practices and
clean regulatory track record.
Continuous investment in R&D, with leading technological capabilities among Indian peers.
Ability to leverage science and existing competencies to increase total addressable market and deepen
intellectual property-driven offerings.
The company derives almost all of its revenue from the sale of APIs, which collectively constituted 96.07%, 99.10%
and 100.00% of the company's revenue from operations in Fiscals 2026, 2025 and 2024, respectively. Further, its top five APIs constituted 62.27%, 63.16% and 60.37% of the company's revenue from operations in Fiscals 2026,
2025 and 2024, respectively. Any reduction in demand for APIs, and its top products in particular, or
disruption in production, could have an adverse effect on the company's business, results of operations, financial
condition and cash flows.
The company's manufacturing facilities is subject to periodic inspections and audits by regulatory authorities and
its customers. Any manufacturing or quality control failures may subject it to regulatory action, damage
the company's reputation and have an adverse effect on its business, results of operations, financial condition and
cash flows.
The company exports its products to various countries and the company's revenue from external customers outside India as per
Ind AS 108 - "Operating Segments" represented 67.04%, 55.19% and 59.97% of its revenue from
operations in Fiscals 2026, 2025 and 2024, respectively. The company's inability to handle risks associated with its
export sales could adversely affect the company's sales to customers in foreign countries, its results of operations,
financial condition and cash flows.
In Fiscals 2026, 2025 and 2024, revenue from the United States represented 13.12%, 4.02% and 8.97% of
the company's revenue from operations. The imposition of tariffs or other anti-outsourcing legislation by the United
States could adversely affect its results of operations, financial condition and cash flows.
The company derives a substantial portion of its revenue from certain key customers. Revenue generated from the company's
top ten customers accounted for 57.59%, 55.90% and 61.65% of its revenue from sale of product in
Fiscals 2026, 2025 and 2024, respectively. Loss of the company's relationship with any of these customers or delays
or reductions in their orders could have an adverse effect on its business, results of operations, financial
condition and cash flows.
The company's manufacturing facilities and dedicated R&D centres are located in the state of Madhya Pradesh in
India. Any adverse developments affecting Madhya Pradesh or its surrounding regions could adversely
affect its business, results of operations, financial condition and cash flows. A slowdown, interruption or
shutdown in the company's manufacturing operations could have an adverse effect on its business, results of
operations, financial condition and cash flows.
The company depends on certain suppliers for raw materials for its operations. Purchases from the company's top ten suppliers
accounted for 25.50%, 18.41% and 50.33% of its total expenses in Fiscals 2026, 2025 and 2024,
respectively. Any loss of such suppliers or non-performance of their obligations could adversely affect the company's
business, results of operations, financial condition and cash flows.
The company operates in a highly competitive market. Its faces competition both within the company's API manufacturing
business and in its role as a CDMO, which the company has recently commenced. An inability to compete
effectively may adversely affect its business, results of operations, financial condition and cash flows.
The company procures a portion of its raw material requirements from different countries, including China and the
United States. Any adverse developments in these countries, or the laws governing the company's imports from these
countries, could disrupt its raw material supply and adversely affect the company's results of operations, financial
condition and cash flows.
The company's success depends on its ability to develop and commercialise new products in a timely manner. If the company's
research and development efforts does not succeed, or the products its commercialise does not perform as
expected, the introduction of new products may be hindered, which could adversely affect the company's business,
results of operations, financial condition and cash flows.
